Where to Inject Tirzepatide: Sites, Technique & Rotation
A practical guide to labeled injection sites, presentation-specific training, safe rotation, and aftercare for Mounjaro, Zepbound, and prescribed compounded products.
Last Updated: June 2026 | Reading Time: 9 minutes | Key point: tirzepatide is labeled for subcutaneous injection into the abdomen, thigh, or back of the upper arm by another person; follow the instructions for your exact presentation.
The Three Tirzepatide Injection Sites
Tirzepatide is labeled for subcutaneous injection, meaning the medicine goes under the skin. The current Zepbound US Prescribing Information (revised August 2026) and Mounjaro US Prescribing Information (revised August 2026) list the abdomen, thigh, or the back of the upper arm when another person gives the injection. Both labels also say to rotate sites with each dose.
Abdomen: choose an area away from the navel and from scars, bruises, or irritated skin. General MSK patient education (accessed October 15, 2026) uses a two-inch boundary around the navel; follow the site instructions from your clinician for your situation.
Thigh: use the labeled thigh area and the instructions you were taught for your exact device. The label does not make every thigh-injection technique interchangeable.
Back of the upper arm: another person should give the injection there. Do not treat the three listed areas as proof that a branded pen, branded vial, or compounded vial uses the same preparation or delivery steps.
This is the same general set of labeled areas discussed for Ozempic, Zepbound, and Wegovy. For general subcutaneous site principles, see our peptide injection sites guide.
How to Inject Tirzepatide Step by Step
First confirm the product name and presentation. Lilly says patients should receive training for the specific presentation they will use and should read the new Instructions for Use if the presentation changes. Do not carry a device step, timing instruction, or other detail from one presentation to another.
Single-dose pen: Mounjaro or Zepbound
The single-dose pen pathway is separate from the vial and KwikPen pathways. For a Zepbound single-dose pen, the FDA-approved Instructions for Use (revised April 2026) says to check the label, dose, expiration, and medicine appearance; wash your hands; keep the pen locked and pull the gray base cap straight off; place the clear base flat against the skin, then unlock, press and hold up to 10 seconds, and confirm the gray plunger is visible after the first and second clicks. Put the used pen in an FDA-cleared sharps container immediately.
The Mounjaro single-dose pen Instructions for Use (revised April 2026) says to check the label and medicine, leave the gray base cap on while preparing, pull it straight off while the pen is still locked, place the clear base flat against the skin, unlock, press and hold the purple button up to 10 seconds, and confirm the gray plunger after the first and second clicks before placing the used pen in a sharps container. Use the IFU that matches the pen in your hand. For related background, see our Mounjaro pen instructions and Mounjaro injection technique guides, then verify against the current product IFU.
Single-dose vial
For a branded single-dose vial, the current Zepbound Instructions for Use (revised April 2026) directs patients to check the label and medicine, wash their hands, use a new syringe and needle, wipe the stopper, prepare the labeled dose as the clinician showed them, keep the needle in the skin for the labeled completion interval, apply gauze without rubbing if needed, and place the used syringe and needle in a sharps container. The Mounjaro single-dose vial Instructions for Use (revised April 2026) has its own brand-specific steps. A single-dose vial is not a generic template for a compounded vial.
Multi-dose vial
For a branded multi-dose vial, use the current label and the matching Zepbound Instructions for Use (revised January 2026) or Mounjaro Instructions for Use (revised January 2026). Each current IFU has separate preparation, dose-measurement, site, completion, storage, and disposal directions and requires a new syringe and needle for each injection. Do not substitute directions from a single-dose vial, another product, or an online chart.
Single-patient-use KwikPen
A Mounjaro or Zepbound KwikPen is a disposable multi-dose, single-patient-use pen with four fixed doses. Use the illustrated Mounjaro KwikPen Instructions for Use (revised January 2026) or Zepbound KwikPen Instructions for Use (revised January 2026) that matches your pen. The full IFU shows needle attachment, priming before each weekly injection, dose selection, the distinct dose-window indicators for selection and completion, and needle removal and disposal. These illustrations are essential; the single-dose pen steps above are not KwikPen instructions. After four doses, discard the pen with any unused medicine. Do not inject leftover medicine, transfer it to a syringe, or share the pen.
Compounded multi-dose vial
A compounded vial is not automatically interchangeable with a branded vial or pen. Ask the prescriber, pharmacist, or compounder to show you how to read the current label and administer the prescribed dose. Do not infer a unit count, reconstitution recipe, concentration, or needle angle from the branded steps above. The tirzepatide dosage chart and compounded tirzepatide dosage guide are educational context only and cannot replace that product-specific instruction.
FDA guidance on unapproved GLP-1 drugs (content current October 1, 2026) says compounded drugs are not FDA approved and encourages patients to ask their health care provider or compounder how to measure and administer the intended dose.
Dose Math: Label-Dependent Calculator
The calculator below is an educational arithmetic tool. Use it only after you have the prescribed milligram dose, the exact pharmacy-labeled total amount and volume, and the labeled concentration, and only when your clinician or pharmacist confirms that a unit conversion is appropriate for your equipment. A preset such as 10 mg, 2 mL, or a U-100 scale is not a personal dosing instruction. Do not use the calculator to mix or reconstitute branded or compounded tirzepatide, choose a dose, or turn a titration week into a universal unit count.
Peptide Reconstitution Calculator
Calculate concentration and volume arithmetic from entered product values
Starting mass is an illustrative example. Replace it with the amount shown on the actual product label.
Enter the total volume after mixing, not the vial capacity. The starting mass and 2 mL volume are illustrative examples, not a prescribed regimen. The calculator does not select a diluent; use product-specific preparation instructions.
Optional arithmetic input; no amount is preselected. Results are calculated quantities, not dose recommendations.
Used only for theoretical arithmetic duration; it is not a treatment schedule or shelf-life calculation.
Enter peptide amount, final solution volume, and desired dose to see calculations
Disclaimer: This calculator is for research and educational purposes only. It is not medical advice. Always consult with a healthcare professional before using any peptide product. Verify all calculations independently.
The how to reconstitute peptides guide, bacteriostatic water explainer, and peptide calculator are general educational references. None is a direction to mix or reconstitute tirzepatide or to select a patient-specific unit amount.
FDA label-strength guidance (updated May 21, 2024) describes confusion when total volume and amount per milliliter are expressed differently. Read the current pharmacy label with the prescriber or pharmacist before any conversion.
How to Rotate Sites (and Why It Matters)
Rotate sites with each dose, as the current Mounjaro and Zepbound labels direct. Write down the site you used and choose another suitable site next time. A simple log helps you remember which site you used.
Keep injections away from the navel, scars, bruises, and irritated or injured skin. General MSK education uses a two-inch boundary around the navel and recommends documenting the site and using a different site each time. It does not establish a universal weekly one-inch or finger-width rule, and clockwise rotation is optional rather than required. For broader context, see our how to inject peptides guide.
Needle Size and Supplies
Equipment depends on the presentation. Pens use the equipment and needle steps in their current Instructions for Use. Branded vial labels direct patients to use a syringe appropriate for the labeled dose and a new syringe and needle for each injection. A compounded vial must follow its own pharmacy label and prescriber or pharmacist instructions. There is no universal needle length, gauge, or injection angle for every tirzepatide product, and a shorter or finer needle is not a guarantee of less discomfort.
Put used needles and syringes into a sharps disposal container immediately. The FDA sharps-disposal guidance (content current August 10, 2023) says not to reuse sharps containers and to follow community rules for final disposal. Use a new sterile needle and syringe for each dose when the product instructions call for them.
How to Reduce Discomfort and Bruising
A small amount of soreness, bruising, or redness can occur after an injection. Some people feel discomfort, and the cause or significance of a reaction cannot be determined from this page. Follow the preparation and injection steps for the exact presentation, let any skin-cleaning product dry as directed, and do not rub the site afterward. If there is bleeding, apply brief gentle pressure with clean gauze or cotton.
Contact your clinician for bleeding that does not stop, severe pain, fever, swelling, itching, rash, or another concerning symptom. Lilly labeling includes injection-site reactions and hypersensitivity reactions; seek prompt medical attention if a serious allergic reaction is suspected. Do not dismiss a concerning symptom or assume its significance from this page.
MSK aftercare education (accessed October 15, 2026) provides general injection aftercare guidance: use gentle pressure, do not rub, and contact a clinician for concerning symptoms.
What to Avoid
Use the prescribed subcutaneous route and the device-specific instructions. Do not inject into a muscle or vein, or into skin that is bruised, scarred, broken, tender, or hardened. Do not reuse a needle or syringe or leave used sharps loose. Put used sharps in a suitable container immediately and follow local disposal rules. Do not share a single-patient-use KwikPen or transfer leftover pen medicine into a syringe. If a dose goes into an unintended area or you have severe pain, persistent bleeding, fever, swelling, rash, or another concerning symptom, contact a clinician. For broader medication-safety context, see tirzepatide long-term side effects.
Frequently Asked Questions About Tirzepatide Injections
Current Mounjaro and Zepbound labels identify the abdomen, thigh, and the back of the upper arm when another person gives the injection. They also direct patients to rotate sites with each dose. These locations do not make every device or formulation interchangeable, and the labels do not establish one universal best site. Use the training for the exact presentation you received. For a general two-inch navel boundary, follow the patient-education and clinician instructions that apply to you.
The steps depend on the presentation: single-dose pen, single-dose vial, multi-dose vial, or single-patient-use KwikPen. Read the current Instructions for Use for the exact product and use the presentation-specific training supplied by your clinician or pharmacist. A branded vial requires the syringe specified for its labeled dose and a new syringe and needle for each injection. A KwikPen has its own dose-knob, needle, and disposal steps. For a compounded vial, follow the current pharmacy label and clinician or pharmacist instructions; do not infer a generic device sequence, unit count, reconstitution method, or needle angle from a branded product.
The current Mounjaro and Zepbound labels list the abdomen, thigh, and the back of your upper arm with another person administering the injection for subcutaneous injection and say to rotate sites with each dose. They do not support a universal absorption or effectiveness guarantee for one site. Follow the instructions for your prescribed presentation and ask your clinician if a site is difficult to use or has a skin problem.
Rotate sites with each dose and write down where you injected so you can choose a different site next time. Keep the injection away from the navel, scars, bruises, and irritated or injured skin; the general MSK patient-education video uses a two-inch navel boundary. There is no universal one-inch or finger-width rule and no required clockwise schedule. If your clinician gave you a different site-rotation plan, follow that plan.
There is no single needle length or gauge for every tirzepatide presentation. A pen has presentation-specific equipment. Branded vial labeling says to use a syringe appropriate for the labeled dose and a new syringe and needle for each injection. For compounded tirzepatide, the pharmacy label, prescriber, and pharmacist determine the equipment and technique. Do not select a length, gauge, or angle from a generic chart.
Mild soreness, bruising, or redness can occur after a subcutaneous injection, but no reaction should be assumed to be harmless. Do not rub the site. If there is bleeding, use gentle pressure with clean gauze or cotton; contact your clinician for bleeding that does not stop, severe pain, fever, swelling, itching, rash, or another concerning symptom. Suspected serious hypersensitivity requires prompt medical attention.
No. The same general body areas do not mean that the device, label, concentration, measurement, or training is the same. FDA says compounded drugs are not FDA approved and are not reviewed for safety, effectiveness, or quality before marketing. Ask the prescriber, pharmacist, or compounder to explain the exact label and administration steps for your product. Do not use this page to equate a compounded product with Mounjaro or to create a unit chart or reconstitution plan.
Use the prescribed subcutaneous route and the instructions for the exact presentation. Do not inject into a muscle or vein, use skin that is bruised, scarred, broken, tender, or hardened, or reuse a needle or syringe. Put used sharps into a sharps container immediately and follow local disposal rules. Never share a single-patient-use KwikPen or transfer leftover KwikPen medicine into a syringe. Contact a clinician for severe pain, persistent bleeding, fever, swelling, rash, or other concerning symptoms.
Use Your Prescribed Dose Instructions
A titration week does not identify a universal number of units. Before each injection, use the current prescription, pharmacy label, and instructions for the exact device; ask your prescriber or pharmacist if anything conflicts. Our tirzepatide dosage chart is context only and does not replace those instructions.
Review the Tirzepatide Dosage ChartRelated Guides
Peptide Injection Sites
General subcutaneous site and rotation context for injectable peptides.
Compounded Tirzepatide Dosage
Questions to take to your prescriber or pharmacist about a current pharmacy label.
Where to Inject Ozempic
Site-selection context for semaglutide pens; follow that product's current instructions.